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Non-small cell lung cancer (NSCLC) is the most common
cause of cancer related mortality worldwide and in need of
new treatment options. Previously, we have shown that 97
genes are overexpressed in 9 primary NSCLC cell lines by
DNA microarray technology. Pyruvate kinase M2 (PKM2),
an allosteric isoform of pyruvate kinase and metabolic
enzyme necessary for aerobic glycolysis and cell prolifera-
tion, was identified to be over-expressed in the NSCLC
cell lines. Real-time qRT-PCR and immunohistochemistry
(IHC) techniques confirmed the microarrays results. Con-
sistent with the over-expression of PKM2, all 9 NSCLC
cell lines showed higher PKM2 enzyme activity than nor-
mal lung cell lines. Since a chemical inhibitor of PKM2
decreased PKM2 enzyme activity and proliferation of
NSCLC cell lines, we hypothesized that PKM2 inhibitors
may have a role in antitumor effects in vivo. Therefore, we
evaluated antitumor effects of a PKM2 inhibitor in murine
models of NSCLC. Mice tolerated intra-tumoral adminis-
tration of the PKM2 inhibitor (Small molecule inhibitor
for PKM2) up to 500 µg/kg/day without any evidence of
visible toxicity or weight loss. Despite its anti-proliferative
activities in vitro, the PKM2 inhibitor did not mediate sig-
nificant antitumor effects in NSCLC tumor xenografts.
The mechanism of lack of activity in vivo is not clear. It is
possible that PMK2 inhibitor levels were not sufficient or
sustained in vivo for a measurable antitumor effect.
To further study whether PKM2 was a target for ther-
apy, we silenced the PKM2 gene in the H1299 and H358
NSCLC cell lines using RNAi and proliferative activity of
tumors was assessed in vitro and in vivo. Gene silencing in
cells transfected with plasmids encoding shRNAs was con-
firmed by IHC, which showed >80% silencing measured
by NIKON-S-Element software at the protein level. In
clonogenic assays, we observed >50% fewer colonies in
two PKM2 silenced NSCLC cell lines compared to mock
transfected controls. In subcutaneous xenograft tumor
models in athymic nude mice, preliminary results showed
that PKM2-silenced tumors grew significantly slower com-
pared to mock transfected tumors (p < 0.05). These results
suggest that PKM2 may be a target for cancer therapy.
Additionally, given its over-expression in NSCLC, it may
also serve as a target for immunotherapy. Studies are
ongoing to confirm these results, understand a mechanism
of tumor response, and determine whether patients gener-
ate immune responses to PKM2.
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